Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CC-10004 in active psoriatic arthritis
2006-004619-23Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apremilast in psoriatic arthritis (PsA) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Primary efficacy over 84 days. Started Dec 2006; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2006-004619-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004619-23.